{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=83&status=NOT_YET_RECRUITING",
    "query": {
      "status": "NOT_YET_RECRUITING",
      "page": 83
    },
    "page_size": 10
  },
  "pagination": {
    "page": 83,
    "page_size": 10,
    "total_count": 3253,
    "total_pages": 326,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=84&status=NOT_YET_RECRUITING&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=82&status=NOT_YET_RECRUITING&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:19:25.014Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07484139",
      "title": "H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Cavity Squamous Cell Carcinoma",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "XL092",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2026-09",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Chapel Hill, North Carolina • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07484139"
    },
    {
      "nct_id": "NCT06731075",
      "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "ORMD-0801 8 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule",
          "type": "OTHER"
        },
        {
          "name": "ORMD-0801 16 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Oramed, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-12-15",
      "completion_date": "2027-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06731075"
    },
    {
      "nct_id": "NCT07174401",
      "title": "Rocklatan Retinal Perfusion OCT Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.",
          "type": "DRUG"
        },
        {
          "name": "Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-01",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07174401"
    },
    {
      "nct_id": "NCT07735819",
      "title": "Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Glioma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Minocycline 200mg/day",
          "type": "DRUG"
        },
        {
          "name": "[18F]FETrp PET/CT",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2026-09",
      "completion_date": "2031-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07735819"
    },
    {
      "nct_id": "NCT06876324",
      "title": "Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Alabama",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "HealthMPowerment App",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "14 Years to 21 Years"
      },
      "enrollment_count": 10,
      "start_date": "2026-11",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06876324"
    },
    {
      "nct_id": "NCT07895823",
      "title": "Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Field-based LA-CAB/RPV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2027-01",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07895823"
    },
    {
      "nct_id": "NCT07825389",
      "title": "C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Primary Progressive Multiple Sclerosis",
        "Secondary Progress Multiple Sclerosis (SPMS)",
        "Primary Progressive Multiple Sclerosis (PPMS)",
        "MS",
        "MS (Multiple Sclerosis)",
        "Neuro-Degenerative Disease",
        "Neuro-Degenerative Diseases",
        "Autoimmune"
      ],
      "interventions": [
        {
          "name": "C-CAR168",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbelZeta Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 119,
      "start_date": "2027-02",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 2,
      "location_summary": "Gilbert, Arizona • La Jolla, California",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07825389"
    },
    {
      "nct_id": "NCT06783868",
      "title": "Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Catheter Ablation",
          "type": "DEVICE"
        },
        {
          "name": "Market-approved AVNB, OAC and AAD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Kansas City Heart Rhythm Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-10",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 7,
      "location_summary": "Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Independence",
          "state": "Missouri"
        },
        {
          "city": "Independence",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06783868"
    },
    {
      "nct_id": "NCT07659743",
      "title": "BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "Active BreEStim Treatment",
          "type": "DEVICE"
        },
        {
          "name": "Sham BreEStim Treatment",
          "type": "DEVICE"
        },
        {
          "name": "The TENS Treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "22 Years to 80 Years"
      },
      "enrollment_count": 66,
      "start_date": "2027-01-04",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07659743"
    },
    {
      "nct_id": "NCT06907485",
      "title": "A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pediatric Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Aminolevulinic acid hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Costas Hadjipanayis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2027-08",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-15T13:19:25.014Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06907485"
    }
  ]
}